Emerging therapies for patients with penile cancer
“We still debate and there’s some good data that [supports that] chemotherapy is not that effective for patients with penile cancer,” says Philippe E. Spiess, MD, MS, FACS.
In this video, Philippe E. Spiess, MD, MS, FACS, discusses the challenges of treating penile cancer and new treatment options for these patients, which were topics focused on at the 2021 Society of Urologic Oncology Annual Meeting. Spiess is a genitourinary oncologist and assistant chief of surgical services at the Moffitt Cancer Center in Tampa, Florida.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.
